KBC Group
ONC

KBC Group’s BeOne Medicines Ltd ONC Stock Holding History

KBC Group’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.82M Buy
9,488
+502
+6% +$162K 0.01% 595
2025
Q4 		$2.73M Hold
8,986
– – 0.01% 561
2025
Q3 		$3.06M Hold
8,986
– – 0.01% 520
2025
Q2 		$2.17M Buy
8,986
+49
+0.5% +$12K 0.01% 568
2025
Q1 		$2.43M Hold
8,937
– – 0.01% 561
2024
Q4 		$1.65M Hold
8,937
– – ﹤0.01% 720
2024
Q3 		$2.01M Hold
8,937
– – 0.01% 616
2024
Q2 		$1.27M Hold
8,937
– – ﹤0.01% 641
2024
Q1 		$1.4M Hold
8,937
– – ﹤0.01% 632
2023
Q4 		$1.61M Hold
8,937
– – 0.01% 636
2023
Q3 		$1.61M Sell
8,937
-2,412
-21% -$477K 0.01% 620
2023
Q2 		$2.02M Hold
11,349
– – 0.01% 602
2023
Q1 		$2.45M Hold
11,349
– – 0.01% 615
2022
Q4 		$2.5M Sell
11,349
-2,073
-15% -$380K 0.01% 566
2022
Q3 		$1.81M Sell
13,422
-1,101
-8% -$189K 0.01% 563
2022
Q2 		$2.35M Buy
14,523
+331
+2% +$51.7K 0.01% 515
2022
Q1 		$2.68M Buy
14,192
+125
+0.9% +$26.6K 0.01% 525
2021
Q4 		$3.81M Buy
14,067
+8,720
+163% +$2.94M 0.01% 499
2021
Q3 		$1.94M Sell
5,347
-5,373
-50% -$1.76M 0.01% 664
2021
Q2 		$3.68M Sell
10,720
-492
-4% -$163K 0.01% 682
2021
Q1 		$3.9M Sell
11,212
-2,296
-17% -$760K 0.01% 650
2020
Q4 		$19.2M Buy
13,508
+4,642
+52% +$1.28M 0.01% 669
2020
Q3 		$2.54M Buy
8,866
+564
+7% +$133K 0.01% 670
2020
Q2 		$1.56M Buy
8,302
+2,208
+36% +$359K 0.01% 738
2020
Q1 		$750K Buy
6,094
+130
+2% +$20.3K 0.01% 763
2019
Q4 		$989K Buy
5,964
+2,566
+76% +$426K 0.01% 901
2019
Q3 		$416K Hold
3,398
– – ﹤0.01% 1129
2019
Q2 		$421K Hold
3,398
– – ﹤0.01% 1108
2019
Q1 		$449K Buy
3,398
+776
+30% +$105K ﹤0.01% 1109
2018
Q4 		$368K Buy
+2,622
New +$348K ﹤0.01% 1000

Other funds holding ONC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

KBC Group's ONC Position: Q1 2026 in Review

KBC Group increased its BeOne Medicines Ltd (ONC) stake by 5.6% in Q1 2026, buying an estimated $162K and bringing the position to 9,488 shares worth $2.82M. The position accounts for 0.01% of the portfolio, ranked #595.

KBC Group first reported a position in ONC in Q4 2018 and has held it in 30 quarters since. The position peaked at $19.2M in Q4 2020. 282 funds tracked by Wall St. Rank hold ONC as of Q1 2026.

  • KBC Group held 9,488 shares of BeOne Medicines Ltd worth $2.82M as of Q1 2026.
  • KBC Group bought 502 BeOne Medicines Ltd shares in Q1 2026, an estimated $162K.
  • BeOne Medicines Ltd made up 0.01% of KBC Group's portfolio in Q1 2026, its #595 holding.
  • KBC Group first reported a position in BeOne Medicines Ltd in Q4 2018 and has held it in 30 quarters since.
  • KBC Group's BeOne Medicines Ltd position peaked at $19.2M in Q4 2020.
  • 282 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.